Evidence map›Paper›PMID 35200752›Full record

ArticleMedicines (Basel, Switzerland)2022

In Vitro and In Silico Antimalarial Evaluation of FM-AZ, a New Artemisinin Derivative.

Ioannis Tsamesidis, Farnoush Mousavizadeh, Chinedu O Egwu, Dionysia Amanatidou, Antonella Pantaleo, Françoise Benoit-Vical, Karine Reybier, Athanassios Giannis

Open access · goldAbstract read
In one paragraph

Article in Medicines (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Tropical life sciences research · 2025
    Article
  2. Review
  3. Investigation of new ferrocenyl-artesunate derivatives as antiparasitics.Dalton transactions (Cambridge, England : 2003) · 2023
    Article
  4. Advocacy for the Medicinal PlantMolecules (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Ioannis TsamesidisUMR 152 Pharma-Dev, Universite de Toulouse III, IRD, UPS, 31400 Toulouse, France.ORCID 0000-0002-1439-3920
Farnoush MousavizadehInstitute for Organic Chemistry, University of Leipzig, Johannisallee 29, 04301 Leipzig, Germany.
Chinedu O EgwuUMR 152 Pharma-Dev, Universite de Toulouse III, IRD, UPS, 31400 Toulouse, France.ORCID 0000-0003-3408-5471
Dionysia AmanatidouDepartment of Biomedical Sciences, School of Health, International Hellenic University, 57400 Thessaloniki, Greece.ORCID 0000-0002-5849-4192
Antonella PantaleoDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy.ORCID 0000-0003-2954-7053
Françoise Benoit-VicalLaboratoire de Chimie de Coordination, LCC-CNRS, Universite de Toulouse, 31077 Toulouse, France.
Karine ReybierUMR 152 Pharma-Dev, Universite de Toulouse III, IRD, UPS, 31400 Toulouse, France.
Athanassios GiannisInstitute for Organic Chemistry, University of Leipzig, Johannisallee 29, 04301 Leipzig, Germany.ORCID 0000-0003-2203-0959
Centre National de la Recherche Scientifique · FRLeipzig University · DEUniversité Toulouse III - Paul Sabatier · FRInternational Hellenic University · GRUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artemisinin-based Combination Therapies (ACTs) are currently the frontline treatment against

Indexed as

artemisinin resistancein silico studyLC-MSnovel artemisinin derivativesROS

Identifiers

PMID35200752
PMCPMC8880451
OpenAlexW4210379578

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.